Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.

Abstract

BACKGROUND:

Diffuse intrinsic pontine gliomas have poor prognosis.

OBSERVATION:

We report on 2 patients with diffuse intrinsic pontine glioma treated with radiation, followed by temozolamide 200 mg/m/d for 5 days every 28 days and bevacizumab 10 mg/kg/dose every 14 days. Both patients have ongoing PFS of 37 and 47 months from diagnosis. A decrease in tumor size by >65% was observed in both the patients. Both patients continue treatment. No steroid requirement since 10 weeks after radiation. Quality of life is excellent and the chemotherapy regimen is well tolerated.

CONCLUSIONS:

A clinical trial in an expanded cohort is warranted to determine the toxicity and evaluate response.

• Authors: Dolly G Aguilera, Claire Mazewski, Laura Hayes, Cathy Jordan, Natia Esiashivilli, Anna Janns, Tobey J Macdonald
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 35 Issue 1 Pg. e42-6 (Jan 2013) ISSN: 1536-3678 [Electronic] United States
• PMID: 23249962 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Dacarbazine
• Temozolomide

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab
• Brain Stem Neoplasms (mortality, therapy)
• Chemoradiotherapy
• Child
• Dacarbazine (administration & dosage, analogs & derivatives)
• Female
• Glioma (mortality, therapy)
• Humans
• Magnetic Resonance Imaging
• Male
• Pons
• Prognosis
• Survival Rate
• Temozolomide